Noting that several members of Congress recently demanded that a pharmaceutical company justify the high cost of its hepatitis C drug, the editor-in-chief of Life Science Leader magazine suggests that patent protections for prescription medications may need to be changed and additional incentives offered to achieve the goal of inexpensive drugs. Rob Wright praises the Orphan Drug Act for providing certain incentives, such as waiving some fees and providing tax credits, as well as prescribing “a seven-year period of market exclusivity after [Food and Drug Administration] approval” to address the slow development of rare disease drugs. But he notes that none of the incentives requires that the products be “cheap.” Wright calls for the consideration of longer patents or tying longer patents “to how quickly a company is able to execute its R&D plan or [tying] it to a step-down, drug-pricing exchange model.” In his view, “[a]llowing the application of a ‘one-size-fits-all’ intellectual property policy that affords the same protection for Frisbees as lifesaving and sustaining medicines would be, quite frankly, moronic and short-sighted.” See Life Science Leader, May 30, 2014.